---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-023529"
form_type: "8-K"
ticker: "ESPR"
cik: "0001434868"
company_name: "Esperion Therapeutics, Inc."
filed_at: "2023-02-21T23:59:59+00:00"
generated_at: "2026-06-19T06:47:41.145405+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Esperion Q4 2022 revenue $18.8M (+22% YoY); CLEAR Outcomes trial meets MACE-4 endpoint

## Summary
- CLEAR Outcomes trial met primary MACE-4 endpoint and key secondary endpoints; data to be presented at ACC.23/WCC on March 4, 2023.
- Q4 2022 U.S. net product revenue $15.0M (+23% YoY); full year $55.9M (+40% YoY).
- Net loss Q4 $55.5M ($0.76 per share) vs $65.1M ($1.77) in Q4 2021; full year net loss $233.7M ($3.52) vs $269.1M ($9.31).
- SG&A expenses decreased 37% in Q4 and 41% for full year 2022 vs 2021.
- Entered new $70M ATM sales agreement with Cantor Fitzgerald; terminated prior $250M ATM with Jefferies.

## SEC filing metadata
- accession: 0001104659-23-023529
- form_type: 8-K
- ticker: ESPR
- cik: 0001434868
- company_name: Esperion Therapeutics, Inc.
- filed_at: 2023-02-21T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 1.02, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434868/000110465923023529/0001104659-23-023529-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434868/000110465923023529/tm237313d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-023529
- JSON: https://secwatch.observer/filing/0001104659-23-023529.json
- Plain text: https://secwatch.observer/filing/0001104659-23-023529.txt

## Key facts
- Earnings Releases
  Esperion Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2022 results: revenue $18.8 million, net income net losses of $55.5 million for the fourth quarter of 2022 and $233.7 million for the full year ended December 31, 2022, EPS basic and diluted net losses per share of $0.76 for the fourth quarter of 2022 and $3.52 for the year ended December 31,.
  - Period: the fourth quarter and full year ended December 31, 2022
  - Revenue: $18.8 million
  - Net income: net losses of $55.5 million for the fourth quarter of 2022 and $233.7 million for the full year ended December 31, 2022
  - EPS: basic and diluted net losses per share of $0.76 for the fourth quarter of 2022 and $3.52 for the year ended December 31,
  - Result: reported results
  source text: consumer and brand awareness in their national fanbase Fourth Quarter and Full Year 2022 Financial Results Total revenue for the fourth quarter ended December 31, 2022, was $18.8 million and $75.5 million for the full year ended December 31, 2022, compared to $15.4 million and $78.4 million for the comparable periods in 2021, an increase of 22% and a decrease of
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434868/000110465923023529/0001104659-23-023529-index.htm
- Material Agreements
  Esperion Therapeutics, Inc. terminated Open Market Sale Agreement with Jefferies LLC valued at the Company terminated the 2021 Sales Agreement, effective as of February 21, 2023 (effective 2023-02-21).
  - Action: termination
  - Agreement: atm program
  - Counterparty: Jefferies LLC
  - Value: the Company terminated the 2021 Sales Agreement, effective as of February 21, 2023
  - Effective: 2023-02-21
  source text: In connection with the Company’s entry into the 2023 Sales Agreement, the Company terminated the 2021 Sales Agreement, effective as of February 21, 2023, pursuant to Section 7(b)(i) thereof.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434868/000110465923023529/0001104659-23-023529-index.htm
- Material Agreements
  Esperion Therapeutics, Inc. entered into Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co. valued at up to $70,000,000 of shares of the Company's common stock (effective 2023-02-21).
  - Action: entry
  - Agreement: atm program
  - Counterparty: Cantor Fitzgerald & Co.
  - Value: up to $70,000,000 of shares of the Company's common stock
  - Effective: 2023-02-21
  source text: On February 21, 2023, Esperion Therapeutics, Inc. (the “Company”) entered into a Controlled Equity Offering SM Sales Agreement (the “2023 Sales Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), pursuant to which the Company may sell, from time to time, at its option, up to an aggregate of $70,000,000 of shares of the Company’s common stock, $0.001 par value per share (the “Shares”), through the Agent, as the Company’s sales agent (the “ATM Offering”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434868/000110465923023529/0001104659-23-023529-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.